{"entity":{"id":"nct06868277","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","aka":["ARTEMIDE-Lung04"],"tldr":"A phase 3 trial of Rilvegostomig and Pembrolizumab in non-small-cell lung cancer, run by AstraZeneca, now recruiting.","summary":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06868277 by AstraZeneca, with 830 participants planned, started 2025-04-10 and due to reach its primary completion in 2030-01-17. Interventions recorded: Rilvegostomig and Pembrolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06868277","url":"https://clinicaltrials.gov/study/NCT06868277"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","pdl1-high-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["rilvegostomig","pembrolizumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06868277","phase":"3","setting":"A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)","sponsor":"AstraZeneca","participation":[{"nct":"NCT06868277","source":"https://clinicaltrials.gov/study/NCT06868277","fetchedAt":"2026-10-07T16:55:12.940Z","studySha256":"fd671611bb69d94a74ad21e860d63d0fb19ea57e9f667051aa7039b99cae1d3f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":830,"enrolmentType":"ESTIMATED","siteCount":304,"recruitingSiteCount":247,"countries":["Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Costa Rica","France","Georgia","Germany","Greece","Ireland","Israel","Italy","Japan","Malaysia","Portugal","Romania","South Korea","Spain","Switzerland","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-04-10","startedType":"actual","enrolled":830,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06868277/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}